Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29710269 | 1.00 | FDPS (0.50) | FDPSLTA4HNAPRTCYP1A2CYP2D6 | |
| Bromide SCHEMBL29427100 | 0.98 | FDPS (0.49) | FDPSLTA4HNAPRTCYP1A2CYP2D6 | |
| Bromide SCHEMBL25408048 | 0.98 | FDPS (0.49) | FDPSLTA4HNAPRTCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6168991 | 0.98 | FDPS (0.49) | FDPSLTA4HNAPRTCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7347040 | 0.96 | FDPS (0.47) | FDPSLTA4HNAPRTCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6981996 | 0.81 | CHRNA7 (0.52) | LTA4HCYP1A2CYP2D6HIF1ACHRNA7 | |
| Hydrochloric Acid SCHEMBL494 | 0.81 | SNCA (0.63) | CYP1A2CYP2D6CYP2C19HIF1ASNCA | |
| Hydrochloric Acid SCHEMBL28828301 | 0.79 | SNCA (0.61) | CYP1A2CYP2D6CYP3A4CYP2C19HIF1A | |
| Bromide SCHEMBL8331435 | 0.79 | SNCA (0.64) | CYP1A2CYP2D6CYP3A4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL27993385 | 0.79 | SNCA (0.61) | CYP1A2CYP2D6CYP3A4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | claimed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | claimed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | claimed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | ALLERGAN, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3156387-B1 | METHOD OF PREPARING INDENE DERIVATIVES | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-07-25 | — | — | EP | disclosed |
| EP-3277704-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-1993021186-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-28 | — | — | WO | disclosed |
| EP-0544821-A1 | INDOLE DERIVATIVES AS ANTIALLERGY AND ANTIINFLAMMATORY AGENTS. | PFIZER (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5153214-A | Treating cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1992006088-A1 | INDOLE DERIVATIVES AS ANTIALLERGY AND ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| US-5025025-A | Cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0405391-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1991-01-02 | — | — | EP | disclosed |
| US-4551457-A | GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1985-11-05 | — | — | US | disclosed |
| US-4490376-A | ANTIULCER AND SECRETORY AGENTS | FARMITALIA CARLO ERBA S.P.A (IT) | 1984-12-25 | — | — | US | disclosed |
| US-4444773-A | ANTIULCER, ANTISECRETORY, ANTIINFLAMMATORY | FARMITALIA CARLO ERBA S.P.A. (IT) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | FDPS 1765/4885LTA4H 2092/4885NAPRT 3051/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | FDPS 1765/4885LTA4H 2092/4885NAPRT 3051/4885 |
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | CHP1, UACA, CRYAB | FDPS 1417/4885LTA4H 661/4885NAPRT 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.